|
1
|
Mak LY, Liu K, Chirapongsathorn S, Yew KC, Tamaki N, Rajaram RB, Panlilio MT, Lui R, Lee HW, Lai JC, et al: Liver diseases and hepatocellular carcinoma in the Asia-Pacific region: Burden, trends, challenges and future directions. Nat Rev Gastroenterol Hepatol. 21:834–851. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen J, He F, Peng H and Guo J: The underlying mechanism and targeted therapy strategy of miRNAs cross-regulating EMT process through multiple signaling pathways in hepatocellular carcinoma. Front Mol Biosci. 11:13783862024. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jin X, Dong H, Wang J, Ou G, Lai X, Tian X, Wang L, Zhuang H, Li T and Xiang K: HBx facilitates drug resistance in hepatocellular carcinoma via CD133-regulated self-renewal of liver cancer stem cells. J Clin Transl Hepatol. 13:15–24. 2025.PubMed/NCBI
|
|
4
|
Mitsopoulos P, Lapohos O, Weraarpachai W, Antonicka H, Chang YH and Madrenas J: Stomatin-like protein 2 deficiency results in impaired mitochondrial translation. PLoS One. 12:e01799672017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Li P, Fan Z, Huang Y, Luo L and Wu X: Mitochondrial dynamics at the intersection of macrophage polarization and metabolism. Front Immunol. 16:15208142025. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ma W, Chen Y, Xiong W, Li W, Xu Z, Wang Y, Wei Z, Mou T, Wu Z, Cheng M, et al: STOML2 interacts with PHB through activating MAPK signaling pathway to promote colorectal Cancer proliferation. J Exp Clin Cancer Res. 40:3592021. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Qin C, Wang Y, Zhao B, Li Z, Li T, Yang X, Zhao Y and Wang W: STOML2 restricts mitophagy and increases chemosensitivity in pancreatic cancer through stabilizing PARL-induced PINK1 degradation. Cell Death Dis. 14:1912023. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sun F, Ding W, He JH, Wang XJ, Ma ZB and Li YF: Stomatin-like protein 2 is overexpressed in epithelial ovarian cancer and predicts poor patient survival. BMC Cancer. 15:7462015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cao W, Zhang B, Li J, Liu Y, Liu Z and Sun B: SLP-2 overexpression could serve as a prognostic factor in node positive and HER2 negative breast cancer. Pathology. 43:713–718. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Team RC, . R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing; 2023
|
|
11
|
Therneau TM: A package for survival analysis in R. CRAN2023.
|
|
12
|
Zhao R, Ge Y, Gong Y, Li B, Xiao B and Zuo S: NAP1L5 targeting combined with MYH9 inhibit HCC progression through PI3K/AKT/mTOR signaling pathway. Aging (Albany NY). 14:9000–9019. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yin J, Zhang S, Yang C, Wang Y, Shi B, Zheng Q, Zeng N and Huang H: Mechanotransduction in skin wound healing and scar formation: Potential therapeutic targets for controlling hypertrophic scarring. Front Immunol. 13:10284102022. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hussain MS, Moglad E, Afzal M, Gupta G, Almalki WH, Kazmi I, Alzarea SI, Kukreti N, Gupta S, Kumar D, et al: Non-coding RNA mediated regulation of PI3K/Akt pathway in hepatocellular carcinoma: Therapeutic perspectives. Pathol Res Pract. 258:1553032024. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Subramanian AT, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES and Mesirov JP: Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 102:15545–15550. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liberzon A, Subramanian A, Pinchback R, Thorvaldsdóttir H, Tamayo P and Mesirov JP: Molecular signatures database (MSigDB) 3.0. Bioinformatics. 27:1739–1740. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li X, Zheng Y, Yu K, Hou S, Cui H, Yin R, Zhou Y, Sun Q, Zhang J and Huang C: Stomatin-like protein 2 promotes cell proliferation and survival under 5-Fluorouracil stress in hepatocellular carcinoma. Mol Biol Rep. 51:2282024. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhu W, Li W, Geng Q, Wang X, Sun W, Jiang H and Pu X: Silence of stomatin-like protein 2 represses migration and invasion ability of human liver cancer cells via inhibiting the nuclear factor kappa B (NF-κB) pathway. Med Sci Monit. 24:7625–7632. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zheng Y, Huang C, Lu L, Yu K, Zhao J, Chen M, Liu L, Sun Q, Lin Z, Zheng J, et al: STOML2 potentiates metastasis of hepatocellular carcinoma by promoting PINK1-mediated mitophagy and regulates sensitivity to lenvatinib. J Hematol Oncol. 14:162021. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Guo H, Liang S, Wang Y, Zhou S, Yin D, Zhang S, Wang J, Wu D, Ma K, Liu Y, et al: Cytochrome B5 type A alleviates HCC metastasis via regulating STOML2 related autophagy and promoting sensitivity to ruxolitinib. Cell Death Dis. 13:6232022. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hu H, Zhang H, Han S, Chen J and Xie Y: STOML2 interacts with PHB to activate the MEK/ERK signaling pathway and mediates autophagy-related proteins in the progression of hepatocellular carcinoma. Int J Mol Med. 57:382026.PubMed/NCBI
|
|
22
|
Feng N, Zhang R, Wen X, Wang W, Zhang N, Zheng J, Zhang L and Liu N: RABIF promotes hepatocellular carcinoma progression through regulation of mitophagy and glycolysis. Commun Biol. 7:13332024. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Xu Q, Lan L and Zeng J and Zeng J: The effect of microvascular invasion on hepatocellular carcinoma with portal vein tumor thrombus after hepatectomy: A retrospective study. Cancer Control. 31:107327482412652572024. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhang J, Song X, Li C and Tian Y: Expression and clinical significance of SLP-2 in ovarian tumors. Oncol Lett. 17:4626–4632. 2019.PubMed/NCBI
|
|
25
|
Blanche PD, Dartigues JF and Jacqmin-Gadda H: Estimating and comparing time-dependent areas under receiver operating characteristic curves for censored survival times. Statistics in Medicine. 5381–5397. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Fox M, Mott HR and Owen D: Class IA PI3K regulatory subunits: p110-independent roles and structures. Biochem Soc Trans. 48:1397–1417. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ghalamkari S, Alavi S, Mianesaz H, Khosravian F, Bahreini A and Salehi M: A novel carcinogenic PI3Kα mutation suggesting the role of helical domain in transmitting nSH2 regulatory signals to kinase domain. Life Sci. 269:1187592021. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li X, Lau AYT, Ng ASN, Aldehaiman A, Zhou Y, Ng PKS, Arold ST and Cheung LWT: Cancer-associated mutations in the p85α N-terminal SH2 domain activate a spectrum of receptor tyrosine kinases. Proc Natl Acad Sci USA. 118:e21017511182021. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Shaw AL and Burke JE: Molecular insight on the role of the phosphoinositide PIP3 in regulating the protein kinases Akt, PDK1, and BTK. Biochem Soc Trans. 53:737–749. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chowdhury SM, Zhu X, Aloor JJ, Azzam KM, Gabor KA, Ge W, Addo KA, Tomer KB, Parks JS and Fessler MB: Proteomic analysis of ABCA1-null macrophages reveals a role for stomatin-like protein-2 in raft composition and toll-like receptor signaling. Mol Cell Proteomics. 14:1859–1870. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gong H, Chen S, Liu S, Hu Q, Li Y, Li Y, Li G, Huang K, Li R and Fang L: Overexpressing lipid raft protein STOML2 modulates the tumor microenvironment via NF-κB signaling in colorectal cancer. Cell Mol Life Sci. 81:392024. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Delicato A, Montuori E, Angrisano T, Pollice A and Calabrò V: YB-1 oncoprotein controls PI3K/Akt pathway by reducing pten protein level. Genes (Basel). 12:15512021. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Uzunhisarcıklı E, Bozkurt NM and Sağlam A: ROCK inhibition suppresses glioblastoma via a PTEN-associated reduction in PI3K/AKT signaling. Med Oncol. 42:3722025. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chen J, Zheng W, Li Q, Xu R, Bai T and Pan C: Disruption of lipid raft reverses drug resistance in colorectal cancer cells through the phosphatase and tensin homolog/phosphoinositide 3-kinase/protein kinase B pathway and P-glycoprotein. Neoplasma. 71:571–580. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Qu H, Gao-Wa H, Hou Y, Ren M, Li J, Jing B and Du Y: TRIM37 interacts with PTEN to promote the growth of human T-cell acute lymphocytic leukemia cells through regulating PI3K/AKT pathway. Front Oncol. 12:10167252022. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Keller CR, Martinez SR, Keltz A, Chen M and Li W: Lactate oxidase disrupts lactate-activated RAS and PI3K oncogenic signaling. Cancers (Basel). 16:28172024. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Sang BT, Wang CD, Liu X, Guo JQ, Lai JY and Wu XM: PDGF-BB/PDGFRβ induces tumour angiogenesis via enhancing PKM2 mediated by the PI3K/AKT pathway in Wilms' tumour. Med Oncol. 40:2402023. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Hu Y, Jiang H, Xu Y, Chen G, Fan R, Zhou Y, Liu Y, Yao Y, Liu R, Chen W, et al: Stomatin-like protein 2 deficiency exacerbates adverse cardiac remodeling. Cell Death Discov. 9:632023. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hong M, Zhu H, Liu W, Zhang P, Yu S, Gao Q, Shen G, Li B and Wang G: Scoparone suppresses proliferation and cell cycle of hepatocellular carcinoma cells via inhibiting AKT/GSK-3β/cyclin D1 signaling pathway. Transl Cancer Res. 14:1638–1650. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Chen Y, Liu X, Wang H, Liu S, Hu N and Li X: Akt regulated phosphorylation of GSK-3β/Cyclin D1, p21 and p27 contributes to cell proliferation through cell cycle progression from G1 to S/G2M phase in low-dose arsenite exposed HaCat cells. Front Pharmacol. 10:11762019. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Park S, Kang M, Kim S, An HT, Gettemans J and Ko J: α-Actinin-4 promotes the progression of prostate cancer through the Akt/GSK-3β/β-catenin signaling pathway. Front Cell Dev Biol. 8:5885442020. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Yang F, Chen E, Yang Y, Han F, Han S, Wu G, Zhang M, Zhang J, Han J, Su L and Hu D: The Akt/FoxO/p27Kip1 axis contributes to the anti-proliferation of pentoxifylline in hypertrophic scars. J Cell Mol Med. 23:6164–6172. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Shah MA, Kang JB, Kim MO and Koh PO: Chlorogenic acid alleviates the reduction of Akt and Bad phosphorylation and of phospho-Bad and 14-3-3 binding in an animal model of stroke. J Vet Sci. 23:e842022. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Shultz JC, Goehe RW, Wijesinghe DS, Murudkar C, Hawkins AJ, Shay JW, Minna JD and Chalfant CE: Alternative splicing of caspase 9 is modulated by the phosphoinositide 3-kinase/Akt pathway via phosphorylation of SRp30a. Cancer Res. 70:9185–9196. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Liu C, Xing G, Wu C, Zhu J, Wei M, Liu D, Ge Y, Chen Y, Lei T and Yang Y: Inhibition of expression of the S100A8 gene encoding the S100 calcium-binding protein a8 promotes apoptosis by suppressing the phosphorylation of protein kinase B (Akt) in endometrial carcinoma and HEC-1A cells. Med Sci Monit. 24:1836–1846. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Chibaya L, Karim B, Zhang H and Jones SN: Mdm2 phosphorylation by Akt regulates the p53 response to oxidative stress to promote cell proliferation and tumorigenesis. Proc Natl Acad Sci USA. 118:e20031931182021. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Allgayer H, Mahapatra S, Mishra B, Swain B, Saha S, Khanra S, Kumari K, Panda VK, Malhotra D, Patil NS, et al: Epithelial-to-mesenchymal transition (EMT) and cancer metastasis: The status quo of methods and experimental models 2025. Mol Cancer. 24:1672025. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Feng K, Di Y, Han M, Yan W and Wang Y: SORBS1 inhibits epithelial to mesenchymal transition (EMT) of breast cancer cells by regulating PI3K/AKT signaling and macrophage phenotypic polarization. Aging (Albany NY). 16:4789–4810. 2024.PubMed/NCBI
|
|
49
|
Li Y, Zhang T, Qin S, Wang R, Li Y, Zhou Z, Chen Y, Wu Q and Su F: Effects of UPF1 expression on EMT process by targeting E-cadherin, N-cadherin, Vimentin and Twist in a hepatocellular carcinoma cell line. Mol Med Rep. 19:2137–2143. 2019.PubMed/NCBI
|
|
50
|
Wang X, Xiao Y, Dong Y, Wang Z, Yi J, Wang J, Wang X, Zhou H, Zhang L and Shi Y: A20 interacts with mTORC2 to inhibit the mTORC2/Akt/Rac1 signaling axis in hepatocellular carcinoma cells. Cancer Gene Ther. 30:424–436. 2023.PubMed/NCBI
|
|
51
|
Novoseletskaya E, Grigorieva O, Nimiritsky P, Basalova N, Eremichev R, Milovskaya I, Kulebyakin K, Kulebyakina M, Rodionov S, Omelyanenko N and Efimenko A: Mesenchymal stromal cell-produced components of extracellular matrix potentiate multipotent stem cell response to differentiation stimuli. Front Cell Dev Biol. 8:5553782020. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Zhang QZ, Guo YD, Li HM, Wang RZ, Guo SG and Du YF: Protection against cerebral infarction by Withaferin A involves inhibition of neuronal apoptosis, activation of PI3K/Akt signaling pathway, and reduced intimal hyperplasia via inhibition of VSMC migration and matrix metalloproteinases. Adv Med Sci. 62:186–192. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Delgado-Bellido D, Oliver FJ, Padilla MVV, Lobo-Selma L, Chacón-Barrado A, Díaz-Martin J and de Álava E: VE-cadherin in cancer-associated angiogenesis: A deceptive strategy of blood vessel formation. Int J Mol Sci. 24:93432023. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Lin Y, Jiang Y, Xian H, Cai X and Wang T: Expression and correlation of the Pi3k/Akt pathway and VEGF in oral submucous fibrosis. Cell Prolif. 56:e134912023. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Amir MS, Chiba N, Seong CH, Kusuyama J, Eiraku N, Ohnishi T, Nakamura N and Matsuguchi T: HIF-1α plays an essential role in BMP9-mediated osteoblast differentiation through the induction of a glycolytic enzyme, PDK1. J Cell Physiol. 237:2183–2197. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Wang J, Yang L, Liang F, Chen Y and Yang G: Integrin alpha × stimulates cancer angiogenesis through PI3K/Akt signaling-mediated VEGFR2/VEGF-A overexpression in blood vessel endothelial cells. J Cell Biochem. 120:1807–1818. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Cao C, Zhang L, Sorensen MD, Reifenberger G, Kristensen BW, McIntyre TM and Lin F: D-2-hydroxyglutarate regulates human brain vascular endothelial cell proliferation and barrier function. J Neuropathol Exp Neurol. 82:921–933. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Fendt SM: 100 years of the Warburg effect: A cancer metabolism endeavor. Cell. 187:3824–3828. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Reinfeld BI, Rathmell WK, Kim TK and Rathmell JC: The therapeutic implications of immunosuppressive tumor aerobic glycolysis. Cell Mol Immunol. 19:46–58. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Tian LY, Smit DJ and Jücker M: The role of PI3K/AKT/mTOR signaling in hepatocellular carcinoma metabolism. Int J Mol Sci. 24:26522023. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Fontana F, Giannitti G, Marchesi S and Limonta P: The PI3K/Akt pathway and glucose metabolism: A dangerous liaison in cancer. Int J Biol Sci. 20:3113–3125. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Atkins RJ, Dimou J, Paradiso L, Morokoff AP, Kaye AH, Drummond KJ and Hovens CM: Regulation of glycogen synthase kinase-3 beta (GSK-3β) by the Akt pathway in gliomas. J Clin Neurosci. 19:1558–1563. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Guo J, Jiang X, Lian J, Li H, Zhang F, Xie J, Deng J, Hou X, Du Z and Hao E: Evaluation of the effect of GSK-3β on liver cancer based on the PI3K/AKT pathway. Front Cell Dev Biol. 12:14314232024. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Paskeh MDA, Ghadyani F, Hashemi M, Abbaspour A, Zabolian A, Javanshir S, Razzazan M, Mirzaei S, Entezari M, Goharrizi MAS, et al: Biological impact and therapeutic perspective of targeting PI3K/Akt signaling in hepatocellular carcinoma: Promises and challenges. Pharmacol Res. 187:1065532023. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Zhang L, Gao A and Peng K: PIMREG modulation of PI3K/Akt pathway enhances sorafenib resistance in Huh7 cells. Arab J Gastroenterol. 26:241–249. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Yu L, Xu H, Zhang S, Chen J and Yu Z: SDC1 promotes cisplatin resistance in hepatic carcinoma cells via PI3K-AKT pathway. Human Cell. 33:721–729. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Yin R, Tao Y, Han J, Zhang J, Yu K, Zheng Y, Li X and Huang C: STOML2 inhibits sorafenib-induced ferroptosis in hepatocellular carcinoma via p-AKT signaling pathway. Am J Cancer Res. 15:1614–1628. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Pu X, Dong C, Zhu W, Li W and Jiang H: Silencing stomatin-like protein 2 attenuates tumor progression and inflammatory response through repressing CD14 in liver cancer. Onco Targets Ther. 12:7361–7373. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Zhao Z, Bai M, Wang S, Zhang Y, Liu S, Bao M, Lu S, Cao D, Shen S, Xie L, et al: The inwardly rectifying potassium channel KCNJ12 regulates the stemness of hepatocellular carcinoma cells through the Wnt/β-catenin pathway. J Mol Cell Biol. 2:mjaf0482025. View Article : Google Scholar
|
|
70
|
Zhou C, Li Y, Wang G, Niu W, Zhang J, Wang G, Zhao Q and Fan L: Enhanced SLP-2 promotes invasion and metastasis by regulating Wnt/β-catenin signal pathway in colorectal cancer and predicts poor prognosis. Pathol Res Pract. 215:57–67. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Bam S, Buchanan E, Mahony C and O'Ryan C: DNA methylation of PGC-1α is associated with elevated mtDNA copy number and altered urinary metabolites in autism spectrum disorder. Front Cell Dev Biol. 9:6964282021. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Ryu HY: Histone modification pathways suppressing cryptic transcription. Epigenomes. 8:422024. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Gupta M, Chandan K and Sarwat M: Role of microRNA and long non-coding RNA in hepatocellular carcinoma. Curr Pharm Design. 26:415–428. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Du K, Bai X, Chen L, Shi Y, Wang HD, Cai MC, Sun WQ, Wang J, Chen SY, Jia XB and Lai SJ: Integrated analysis of microRNAs, circular RNAs, long non-coding RNAs, and mRNAs revealed competing endogenous RNA networks involved in brown adipose tissue whitening in rabbits. BMC Genomics. 23:7792022. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Yang X, Zang W, Xuan X, Wang Z, Liu Z, Wang J, Cui J and Zhao G: miRNA-1207-5p is associated with cancer progression by targeting stomatin-like protein 2 in esophageal carcinoma. Int J Oncol. 46:2163–2171. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Lu W, Li H, Liu X, Li A and Xiu R: The RNA-binding proteins MCPIP2 and IGF2BP1 competitively modulate breast tumor angiogenesis by antagonizing VEGFA mRNA stability and expression. FASEB J. 39:e705942025. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Ma X, Liu S, Fan B, Jin D, Miao L, Liu L, Du S and Lin J: Enhancing mRNA translation efficiency by introducing sequence optimized AU-rich elements in 3′ UTR via HuR anchorage. Mol Ther Nucleic Acids. 36:1024852025. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Ren X, Yang W, Yan X and Zhang H: Exploring RNA binding proteins in hepatocellular carcinoma: Insights into mechanisms and therapeutic potential. J Exp Clin Cancer Res. 44:1302025. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Golob-Schwarzl N, Krassnig S, Toeglhofer AM, Park YN, Gogg-Kamerer M, Vierlinger K, Schröder F, Rhee H, Schicho R, Fickert P and Haybaeck J: New liver cancer biomarkers: PI3K/AKT/mTOR pathway members and eukaryotic translation initiation factors. Eur J Cancer. 83:56–70. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Gufler S, Seeboeck R, Schatz C and Haybaeck J: The translational bridge between inflammation and hepatocarcinogenesis. Cells. 11:5332022. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Murgia M, Tan J, Geyer PE, Doll S, Mann M and Klopstock T: Proteomics of Cytochrome C oxidase-negative versus -positive muscle fiber sections in mitochondrial myopathy. Cell Rep. 29:3825–3834. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Mookherjee D, Das S, Mukherjee R, Bera M, Jana SC, Chakrabarti S and Chakrabarti O: RETREG1/FAM134B mediated autophagosomal degradation of AMFR/GP78 and OPA1-a dual organellar turnover mechanism. Autophagy. 17:1729–1752. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Zeng P, Mao J, Guo J, Yang X, Shi Y, Wang X, Song J, Zhou J, Hou L and Liu J: The E3 ubiquitin ligase STUB1 inhibits Senecavirus A replication by mediating VP1 ubiquitination and proteasomal degradation. J Virol. 99:e01152252025. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Tian Z, Xu C, He W, Lin Z, Zhang W, Tao K, Ding R, Zhang X and Dou K: The deubiquitinating enzyme USP19 facilitates hepatocellular carcinoma progression through stabilizing YAP. Cancer Lett. 577:2164392023. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Serricchio M and Bütikofer P: A conserved mitochondrial chaperone-protease complex involved in protein homeostasis. Front Mol Biosci. 8:7670882021. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Kumari S, Sankhwar P, Tripathi R, Kawale AK, Gupta S and Jha RK: Stomatin-like protein-2 promotes aggregation, colonization and migration of endometriotic cells. Reprod Sci. 30:1854–1866. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Chuang CC, Lan YH, Lu YJ, Weng YL and Chen JP: Targeted delivery of irinotecan and SLP2 shRNA with GRP-conjugated magnetic graphene oxide for glioblastoma treatment. Biomater Sci. 10:3201–3222. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Lu YJ, Lan YH, Chuang CC, Lu WT, Chan LY, Hsu PW and Chen JP: Injectable thermo-sensitive chitosan hydrogel containing CPT-11-loaded EGFR-targeted graphene oxide and SLP2 shRNA for localized drug/gene delivery in glioblastoma therapy. Int J Mol Sci. 21:71112020. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Hu G, Zhang J, Xu F, Deng H, Zhang W, Kang S and Liang W: Stomatin-like protein 2 inhibits cisplatin-induced apoptosis through MEK/ERK signaling and the mitochondrial apoptosis pathway in cervical cancer cells. Cancer Sci. 109:1357–1368. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Cheng X, Deng X, Zeng H, Zhou T, Li D and Zheng WV: Silencing of TMED5 inhibits proliferation, migration and invasion, and enhances apoptosis of hepatocellular carcinoma cells. Adv Clin Exp Med. 32:677–688. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Liu Q, Li A, Wang L, He W, Zhao L, Wu C, Lu S, Ye X, Zhao H, Shen X, et al: Stomatin-like protein 2 promotes tumor cell survival by activating the JAK2-STAT3-PIM1 pathway, suggesting a novel therapy in CRC. Mol Ther Oncolytics. 17:169–179. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Zanon A, Guida M, Lavdas AA, Corti C, Rueda MP, Negro A, Pramstaller PP, Domingues FS, Hicks AA and Pichler I: Intracellular delivery of Parkin-RING0-based fragments corrects Parkin-induced mitochondrial dysfunction through interaction with SLP-2. J Transl Med. 22:592024. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Xu H, Chen K, Shang R and Chen X, Zhang Y, Song X, Evert M, Zhong S, Li B, Calvisi DF and Chen X: Alpelisib combination treatment as novel targeted therapy against hepatocellular carcinoma. Cell Death Dis. 12:9202021. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Ye L, Mayerle J, Ziesch A, Reiter FP, Gerbes AL and Toni END: The PI3K inhibitor copanlisib synergizes with sorafenib to induce cell death in hepatocellular carcinoma. Cell Death Discov. 5:862019. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Crabb SJ, Griffiths G, Marwood E, Dunkley D, Downs N, Martin K, Light M, Northey J, Wilding S, Whitehead A, et al: Pan-AKT inhibitor capivasertib with docetaxel and prednisolone in metastatic castration-resistant prostate cancer: A randomized, placebo-controlled phase II trial (ProCAID). J Clin Oncol. 39:190–201. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Mroweh M, Roth G, Decaens T, Marche PN, Lerat H and Jílková ZM: Targeting Akt in hepatocellular carcinoma and its tumor microenvironment. Int J Mol Sci. 22:17942021. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Liu G, Shi A, Wang N, Li M, He X, Yin C, Tu Q, Shen X, Tao Y, Wang Q and Yin H: Polyphenolic Proanthocyanidin-B2 suppresses proliferation of liver cancer cells and hepatocellular carcinogenesis through directly binding and inhibiting AKT activity. Redox Biol. 37:1017012020. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Pervanidis KA, D'Angelo GD, Weisner J, Brandherm S and Rauh D: Akt inhibitor advancements: From capivasertib approval to covalent-allosteric promises. J Med Chem. 67:6052–6063. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Yu K, Shi C, Toral-Barza L, Lucas J, Shor B, Kim JE, Zhang WG, Mahoney R, Gaydos C, Tardio L, et al: Beyond rapalog therapy: Preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2. Cancer Res. 70:621–631. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Hernández-Prat A, Rodriguez-Vida A, Juanpere-Rodero N, Arpi O, Menéndez S, Soria-Jiménez L, Martínez A, Iarchouk N, Rojo F, Albanell J, et al: Novel Oral mTORC1/2 inhibitor TAK-228 has synergistic antitumor effects when combined with paclitaxel or PI3Kα inhibitor TAK-117 in preclinical bladder cancer models. Mol Cancer Res. 17:1931–1944. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Hu YT, Shu ZY, Jiang JH, Xie QF and Zheng SS: Torin2 overcomes sorafenib resistance via suppressing mTORC2-AKT-BAD pathway in hepatocellular carcinoma cells. Hepatobiliary Pancreat Dis Int. 19:547–554. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Guo T, Wu C, Zhang J, Yu J, Li G, Jiang H, Zhang X, Yu R and Liu X: Dual blockade of EGFR and PI3K signaling pathways offers a therapeutic strategy for glioblastoma. Cell Commun Signal. 21:3632023. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Zhang Y, Liu Y, Ma Y, Xu Y, Wang G and Han X: CD93 aggravates cell proliferation, angiogenesis and immune escape in osteosarcoma through triggering the PI3K/AKT pathway. J Orthop Sci. 30:685–691. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Sun X, Chen Y, Tao X, Zhang W, Wang X, Wang X, Ruan Z and Chen Z: INPP4B inhibits glioma cell proliferation and immune escape via inhibition of the PI3K/AKT signaling pathway. Front Oncol. 12:9835372022. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Li B, Feng C, Zhang W, Sun S, Yue D, Zhang X and Yang X: Comprehensive non-coding RNA analysis reveals specific lncRNA/circRNA-miRNA-mRNA regulatory networks in the cotton response to drought stress. Int J Biol Macromol. 253:1265582023. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Tang W and Ma X: Identification of causal plasma proteins in hepatocellular carcinoma via two-sample mendelian randomization and integrative transcriptomic-proteomic analysis. Cancer Res Commun. 5:433–443. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Orang FN and Shadbad MA: CircRNA and lncRNA-associated competing endogenous RNA networks in medulloblastoma: A scoping review. Cancer Cell Int. 24:2482024. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Yum J, Aulia F, Kamiya K, Hori M, Qiao N, Kim BS, Naito M, Ogura S, Nagata T, Yokota T, et al: Hydrophobicity tuning of cationic polyaspartamide derivatives for enhanced antisense oligonucleotide delivery. Bioconjug Chem. 35:125–131. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Liu XM, Zhang Z, Zhong J, Li N, Wang T, Wang L and Zhang Q: Long non-coding RNA MALAT1 modulates myocardial ischemia-reperfusion injury through the PI3K/Akt/eNOS pathway by sponging miRNA-133a-3p to target IGF1R expression. Eur J Pharmacol. 916:1747192022. View Article : Google Scholar : PubMed/NCBI
|
